Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma

Song, Jingjing; Ma, Dawei; Liu, Xiangqi; Chen, Yi‐Chen; Fang, Juan; Lui, Vivian Wai Yan; Zhao, Sijia; Xia, Juan; Cheng, Bin; Wang, Zhi

doi:10.1016/j.clim.2018.02.011

Cited by 4 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thrombomodulin is a tumor suppressive protein that when expressed in several types of cancer cells decreased tumor invasiveness and improved patient survival [85,86]. The level of soluble TM shed from cancer cells to the plasma correlates with disease advancement and is associated with poor prognosis [87,88]. Expression of TM on cancer cells was associated with better differentiation in patients with squamous cell carcinoma of the oral cavity [88].…”

Section: Epcr and Par-1 Interactionsmentioning

confidence: 99%

“…The level of soluble TM shed from cancer cells to the plasma correlates with disease advancement and is associated with poor prognosis [87,88]. Expression of TM on cancer cells was associated with better differentiation in patients with squamous cell carcinoma of the oral cavity [88]. Furthermore, TM decreases PAR-1 and NF-κB activation and significantly suppresses pancreatic cancer tumor growth [89].…”

Section: Epcr and Par-1 Interactionsmentioning

confidence: 99%

See 1 more Smart Citation

Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination

Wojtukiewicz

Hempel

Sierko

et al. 2019

Cancers

View full text Add to dashboard Cite

Endothelial protein C receptor (EPCR) and protease activated receptor 1 (PAR-1) by themselves play important role in cancer growth and dissemination. Moreover, interactions between the two receptors are essential for tumor progression. EPCR is a cell surface transmembrane glycoprotein localized predominantly on endothelial cells (ECs). It is a vital component of the activated protein C (APC)—mediated anticoagulant and cytoprotective signaling cascade. PAR-1, which belongs to a family of G protein–coupled cell surface receptors, is also widely distributed on endothelial and blood cells, where it plays a critical role in hemostasis. Both EPCR and PAR-1, generally considered coagulation-related receptors, are implicated in carcinogenesis and dissemination of diverse tumor types, and their expression correlates with clinical outcome of cancer patients. Existing data explain some mechanisms by which EPCR/PAR-1 affects cancer growth and metastasis; however, the exact molecular basis of cancer invasion associated with the signaling is still obscure. Here, we discuss the role of EPCR and PAR-1 reciprocal interactions in cancer progression as well as potential therapeutic options targeted specifically to interact with EPCR/PAR-1-induced signaling in cancer patients.

show abstract

Section: Epcr and Par-1 Interactionsmentioning

confidence: 99%

Section: Epcr and Par-1 Interactionsmentioning

confidence: 99%

Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination

Wojtukiewicz

Hempel

Sierko

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Thrombomodulin is a 74 kDa membrane receptor expressed on endothelial cells with important roles in physiological coagulation, inflammation and cancer promotion [6,7]. The effects of Thrombomodulin activity in cancer have been linked to its roles in anticoagulation, anti-inflammation and tissue adhesion and proliferation [8].…”

Section: Introductionmentioning

confidence: 99%

The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients

et al. 2020

View full text Add to dashboard Cite

Background Bladder cancer (BC) is the 10th most common cancer in the UK, with about 10,000 new cases annually. About 75–85% of BC are non-muscle invasive (NMIBC), which is associated with high recurrence and progression rates (50–60% within 7–10 years). There are no routine biomarkers currently available for identifying BC patients at increased risk of developing recurrence. The focus of this research study was to evaluate antibody expression in BC patients and their association with cancer recurrence. Methods 35 patients scheduled for TURBT were recruited after written informed consent. Ethical approval for the project was granted via IRAS (REC4: 14/WA/0033). Following surgical procedure, tissues were preserved in 10% buffered formalin and processed within 24 h in FFPE blocks. 7 sections (4 µm each) were cut from each block and stained for CD31, Human epidermal growth factor receptor-2 (HER-2), S100P, Cyclooxygenase-2 (COX-2), VEGFR-3 thrombomodulin and CEACAM-1 using immunohistochemistry. Clinical outcome measures (obtained via cystoscopy) were monitored for up to 6 months following surgical procedure. Results There was significantly increased expression of CD31 (p < 0.001), HER-2 (p = 0.032), S100P (p < 0.001), COX-2 (p < 0.001), VEGFR-3 (p < 0.001) and decreased expression of thrombomodulin (p = 0.010) and CEACAM-1 (p < 0.001) in bladder tumours compared to normal bladder tissues. HER-2 expression was also significantly associated with cancer grade (p = 0.003), especially between grade 1 and grade 2 (p = 0.002) and between grade 1 and grade 3 (p = 0.004). There was also a significant association between cancer stage and HER-2 expression (p < 0.001). Although recurrence was significantly associated with cancer grade, there was no association with antibody expression. Conclusion Findings from the present study may indicate an alternative approach in the monitoring and management of patients with BC. It is proposed that by allowing urological surgeons access to laboratory markers such as HER-2, Thrombomodulin and CD31 (biomarker profile), potentially, in the future, these biomarkers may be used in addition to, or in combination with, currently used scoring systems to predict cancer recurrence. However, verification and validation of these biomarkers are needed using larger cohorts.

show abstract

Immunohistochemical analysis of thrombomodulin expression in myocardial tissue from autopsy cases of ischemic heart disease

et al. 2021

View full text Add to dashboard Cite

Thrombomodulin (TM) in tumor cell differentiation and periphery blood immune microenvironment in oral squamous cell carcinoma

Cited by 4 publications

References 30 publications

Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination

Endothelial Protein C Receptor (EPCR), Protease Activated Receptor-1 (PAR-1) and Their Interplay in Cancer Growth and Metastatic Dissemination

The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients

Immunohistochemical analysis of thrombomodulin expression in myocardial tissue from autopsy cases of ischemic heart disease

Contact Info

Product

Resources

About